Primary Treatment: Treatment · No Placebo Group · N/A
Screening: ~3 weeks
Reporting: 1-6 hours postoperatively
Closest Location: Key-Whitman Eye Center · Dallas, TX
2016First Recorded Clinical Trial
2 TrialsResearching Myopia
10 CompletedClinical Trials
Age 18 - 65 · All Participants · 7 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You are able to read, understand and provide written informed consent on the Institutional Review Board (IRB) approved informed consent form (ICF) and provide authorization as appropriate for local privacy regulations.
You have moderate to high myopia.
You have moderate to high myopia with astigmatism.
You are able and willing to return for scheduled follow-up examinations after surgery.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.